Search details
1.
MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade.
Immunity
; 44(3): 609-621, 2016 Mar 15.
Article
in English
| MEDLINE | ID: mdl-26944201
2.
Role of PD-1 during effector CD8 T cell differentiation.
Proc Natl Acad Sci U S A
; 115(18): 4749-4754, 2018 05 01.
Article
in English
| MEDLINE | ID: mdl-29654146
3.
Precision-activated T-cell engagers targeting HER2 or EGFR and CD3 mitigate on-target, off-tumor toxicity for immunotherapy in solid tumors.
Nat Cancer
; 4(4): 485-501, 2023 04.
Article
in English
| MEDLINE | ID: mdl-36997747
4.
Pillars article: Sequential interactions of the TCR with two distinct cytoplasmic tyrosine kinases. Science. 1994. 263: 1136-1139.
J Immunol
; 193(9): 4279-82, 2014 Nov 01.
Article
in English
| MEDLINE | ID: mdl-25326545
5.
New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016.
J Immunother Cancer
; 5: 50, 2017.
Article
in English
| MEDLINE | ID: mdl-28649381
6.
Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1.
Clin Cancer Res
; 18(24): 6580-7, 2012 Dec 15.
Article
in English
| MEDLINE | ID: mdl-23087408
Results
1 -
6
de 6
1
Next >
>>